Biomarker-guided combination treatment for residual multiple sclerosis activity
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This early-phase study tests combination treatments for multiple sclerosis (MS) based on lab “biomarkers” found in the spinal fluid. It aims to reduce ongoing MS activity and help determine which treatment combinations may work best for different people.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of multiple sclerosis (MS).
- You are 18 years or older.
- Your MS disability level falls within EDSS 1.0 to 7.5.
- You must fit either the “progressing” or “residual disability” group based on specific scores over time.
- If you can become pregnant, you must use effective birth control during the study.
- You must be able and willing to follow all study steps and give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
This study tests a new treatment called SYS6020 for people with multiple sclerosis (MS) that has not improved with standard therapies. The treatment aims to reduce MS activity and disability progression.
This trial tests whether a simple, non-invasive treatment called remote ischemic conditioning — using brief cycles of a blood pressure cuff on your arm — can improve walking and slow disability in people with primary progressive MS. It targets people with moderate disability who have trouble walking.
This trial tests a comprehensive rehabilitation programme for people with multiple sclerosis to see if it can improve their physical abilities and quality of life. Participants will attend regular physiotherapy sessions and undergo clinical and MRI examinations to track changes.
This study tests a new treatment that combines a type of immune cell therapy with a targeted antibody to see if it can help people with multiple sclerosis. It aims to reduce the immune system's attack on the nervous system and potentially slow disease progression.
This trial tests an experimental oral drug called VT7208 in both healthy volunteers and people with multiple sclerosis (MS). The goal is to see if it is safe and how the body processes it, which could lead to a new treatment option for MS.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.